Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 8885 results

  1. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

  2. Sabizabulin for treating COVID-19 [TSID11814]

    Awaiting development Reference number: GID-TA11226 Expected publication date: TBC

  3. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

  4. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development Reference number: GID-TA11224 Expected publication date: TBC

  5. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

  6. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]

    Awaiting development Reference number: GID-TA11194 Expected publication date: TBC

  7. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

  8. NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

    Topic prioritisation

  9. Natural Cycles for monitoring fertility

    Topic prioritisation

  10. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Topic prioritisation

  11. Arthrosamid for symptomatic treatment of knee osteoarthritis

    Topic prioritisation

  12. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

    Topic prioritisation

  13. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

  14. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    In development Reference number: GID-TA11866 Expected publication date: TBC